Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment
Authors:
Open Access
- 30 June 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (6) , e101072
Abstract
Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the number of individuals in Australia who would have been likely to avoid legal blindness or visual impairment due to neovascular age-related macular degeneration over a 2-year period as a result of intravitreal ranibizumab injections. The modelling approach used existing data for the incidence of neovascular age-related macular degeneration in Australia and outcomes from ranibizumab trials. Blindness and visual impairment were defined as visual acuity in the better-seeing eye of worse than 6/60 or 6/12, respectively. In 2010, 14 634 individuals in Australia were estimated to develop neovascular age-related macular degeneration who would be eligible for ranibizumab therapy. Without treatment, 2246 individuals would become legally blind over 2 years. Monthly 0.5 mg intravitreal ranibizumab would reduce incident blindness by 72% (95% simulation interval, 70–74%). Ranibizumab given as needed would reduce incident blindness by 68% (64–71%). Without treatment, 4846 individuals would become visually impaired over 2 years; this proportion would be reduced by 37% (34–39%) with monthly intravitreal ranibizumab, and by 28% (23–33%) with ranibizumab given as needed. These data suggest that intravitreal injections of ranibizumab, given either monthly or as needed, can substantially lower the number of cases of blindness and visual impairment over 2 years after the diagnosis of neovascular age-related macular degeneration.Keywords
This publication has 26 references indexed in Scilit:
- ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATIONRetina, 2014
- Neovascular AMD: an overlooked risk factor for injurious fallsOsteoporosis International, 2009
- Burden and Health Care Resource Utilization in Neovascular Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2007
- Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional studyBritish Journal of Ophthalmology, 2007
- Ten-Year Incidence and Progression of Age-Related MaculopathyOphthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Global data on visual impairment in the year 2002.2004
- Potential Public Health Impact of Age-Related Eye Disease Study ResultsArchives of Ophthalmology (1950), 2003
- Associations of visual function with physical outcomes and limitations 5 years later in an older populationOphthalmology, 2003
- Visual Impairment and Falls in Older Adults: The Blue Mountains Eye StudyJournal of the American Geriatrics Society, 1998